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Abstract
Background The ongoing injection drug use (IDU) crisis in the United States has been
complicated by an emerging epidemic of Staphylococcus aureus IDU-associated bloodstream
infections (IDU-BSI).
Methods We performed a case-control study comparing S. aureus IDU-BSI and non-IDU BSI
cases identiﬁed in a large US Midwestern academic medical center between Jan 1, 2016 and
Dec 21, 2019. We obtained the whole-genome sequences of 154 S. aureus IDU-BSI and 91 S.
aureus non-IDU BSI cases, which were matched with clinical data. We performed phylogenetic and comparative genomic analyses to investigate clonal expansion of lineages and
molecular features characteristic of IDU-BSI isolates.
Results Here we show that patients with IDU-BSI experience longer durations of bacteremia
and have lower medical therapy completion rates. In phylogenetic analyses, 45/154 and 1/91
contemporaneous IDU-BSI and non-IDU BSI staphylococcal isolates, respectively, group into
multiple, unique clonal clusters, revealing that pathogen community transmission distinctively
spurs IDU-BSI. Lastly, multiple S. aureus lineages deﬁcient in canonical virulence genes are
overrepresented among IDU-BSI, which may contribute to the distinguishable clinical presentation of IDU-BSI cases.
Conclusions We identify clonal expansion of multiple S. aureus lineages among IDU-BSI
isolates, but not non-IDU BSI isolates, in a community with limited access to needle exchange
facilities. In the setting of expanding numbers of staphylococcal IDU-BSI cases consideration
should be given to treating IDU-associated invasive staphylococcal infections as a communicable disease.

Plain language summary
Persons who inject drugs are at
increased risk of developing a bloodstream infection caused by the bacterium Staphylococcus aureus. To
investigate whether this risk is due to
transmission of the bacterium within
this community, we compared the
complete set of genes (genome) of S.
aureus isolated from people with
bloodstream infections who do and
do not inject drugs. S. aureus causing
bloodstream infections in persons
who inject drugs were much more
likely to belong to one of multiple
networks of very closely related
subtypes, demonstrating that in some
communities the bacteria causing
this type of infection can likely be
directly transmitted from person to
person through high-risk injection
drug use practices, such as sharing
needles. Therefore, invasive infections in persons who inject drugs can
spread like communicable diseases
and this can inform future policy on
how to prevent them.

1 Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA. 2 The Edison Family Center for Genome Sciences and
Systems Biology, Washington University School of Medicine, St. Louis, MO, USA. 3 Department of Pathology and Immunology, Washington University School
of Medicine, St. Louis, MO, USA. 4 Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA. 5 Department of
Biomedical Engineering, Washington University in St. Louis, St. Louis, MO, USA. 6These authors contributed equally: Laura R. Marks, Juan J. Calix.
✉email: cburnham@wustl.edu; dantas@wustl.edu

COMMUNICATIONS MEDICINE | (2021)1:52 | https://doi.org/10.1038/s43856-021-00053-9 | www.nature.com/commsmed

1

ARTICLE

T

COMMUNICATIONS MEDICINE | https://doi.org/10.1038/s43856-021-00053-9

he injection drug use (IDU) crisis in the United States (US)
is complicated by emerging syndemics of infectious diseases among people who inject drugs (PWID). Since 2015
the Centers for Disease Control and Prevention and health
departments across the US have identiﬁed human immunodeﬁciency virus (HIV) and viral hepatitis outbreaks attributed to
bloodborne transmission within IDU networks1,2. Co-epidemics
of invasive bacterial infections among PWID have also been
identiﬁed3,4. Staphylococcus aureus is the most common pathogen
causing these invasive infections, which are often associated with
staphylococcal bloodstream infection (BSI)5,6. PWID are
approximately 16.3 times more likely than peers to develop
invasive staphylococcal infections, with one in every ten invasive
staphylococcal infections in the US now related to IDU5. Efforts
against invasive staphylococcal infections in general are complicated by the existence of multiple disease subtypes, including
central line-associated BSI (CLABSI), endocarditis, osteomyelitis,
septic arthritis, epidural abscess. Each disease manifestation
necessitates preventative and therapeutic strategies tailored to
characteristic epidemiology, pathobiology, and host risk
factors7,8. However, the epidemiology and transmission of IDUassociated S. aureus invasive infections is poorly deﬁned, as few
studies have investigated it as a separate disease entity.
Staphylococcal IDU-associated bloodstream infections (IDUBSI) may be spurred by factors characteristic of PWID, but absent
among individuals with conventional forms of BSI (cBSI). For
example, high rates of S. aureus contamination of cookers and
ﬁlters used in preparation of controlled-release opioids for IDU
have been observed9. Alternatively, it is speculated that personto-person transmission through contaminated needles contributes to IDU-associated infections. Early reports on an IDUassociated outbreak in Detroit, US identiﬁed being unhoused and
shared injection equipment as risk factors10, and phage typing
and antibiotic susceptibility data identiﬁed common S. aureus
lineages shared by many of these cases11. Subsequent reports
further argued a link between IDU and transmission of
methicillin-resistant S. aureus (MRSA) lineages among
PWID12–14. However, these studies lacked comparator groups
and/or employed low-resolution molecular methods and small
cohort sizes, which limits the interpretation of their ﬁndings. As
community IDU-associated transmission represents an attractive
target for BSI prevention, the existence and impact of person-toperson transmission of pathogenic strains among PWID must be
clearly established.
Other ﬁndings support distinguishing IDU-BSI from cBSI.
IDU-associated staphylococcal infections have been associated
with prolonged bacteremia duration and infectious sequelae such
as endocarditis, possibly due to challenges faced by PWID in
completing the standard-of-care, multiweek treatment regimens
prescribed by guidelines5. Despite these poor prognostic indicators, emerging evidence suggests that, compared to cBSI, IDU-BSI
exhibits comparable to lower mortality rates15–20. A mix of host
and pathogen factors likely inﬂuence these discrepant observations. However, the paucity of studies comparing IDU-BSI to
non-IDU staphylococcal BSI has resulted in a critical knowledge
gap in our understanding of unique factors governing IDUassociated invasive disease.
We hypothesize that features unique to PWID mediate biological differences between S. aureus IDU-BSI and cBSI. Firstly,
shared behaviors and socioeconomic conditions associated with
IDU may predispose to characteristic clonal expansion of S.
aureus pathogenic strains among PWID, raising the possibility
that IDU-BSI is a communicable disease. Secondly, IDU practices
predispose to direct inoculation of bacteria into the bloodstream.
This bypass of major immunological barriers may obviate the role
of microbial factors that mediate early stages of infection in cBSI
2

and permit a wider diversity of otherwise-less virulent S. aureus
strains to cause invasive disease in PWID. To investigate this, we
performed extensive comparative genomic analysis of clinical
isolates in a case-control study of S. aureus BSI occurring in a
large U.S. Midwest medical center over a 4-year period. We
identiﬁed clonal expansion of multiple S. aureus lineages among
IDU-BSI isolates, but not non-IDU BSI isolates, in a community
with limited access to needle exchange facilities.
Methods
Setting and case deﬁnitions. This study was approved by the
Institutional Review Board of Washington University in St. Louis
(IRB# 201804183, 201907187, 201911072, 202007171). A waiver
of informed consent was granted by the Washington University
IRB for isolate collection as all S. aureus specimens were obtained
during routine clinical care and saved for quality improvement
purposes. A waiver of informed consent for data abstraction from
the chart was issued as data were pre-existing in the chart and
many patients were already deceased or would otherwise have
been unable to be contacted. This study was performed at BarnesJewish Hospital (BJH), a 1250-bed, academic, tertiary care center
serving the greater metropolitan area of St. Louis, Missouri and
surrounding areas. Through electronic health record (EHR)
review, we retrospectively identiﬁed cases between 1/2016–1/2019
associated with S. aureus recovered from blood cultures or heart
valve surgical specimens during routine medical care, as described
previously21. We also included cases prospectively identiﬁed
between 1/2019-12/2019 as part of a local quality improvement
initiative and a CDC Developing Healthcare Safety Research
Contract. Only the ﬁrst documentation of infection per patient
was included in our analysis, and the date of the ﬁrst S. aureus
isolate per patient (“index date”) was identiﬁed for each case.
Cases were manually reviewed by an infectious diseases physician
(L.R.M.) and classiﬁed as “IDU-BSI” (deﬁned as IDU directly
preceding index date) or “non-IDU” (cases lacking history of any
mode of substance use), as described previously21. Patient
demographics, drug use history, clinical course, and clinical
microbiological data were obtained from EHR. Duration of bacteremia was deﬁned as the number of calendar days between
index date and date of last positive surveillance blood culture22.
Prolonged bacteremia was deﬁned as duration of culture-proven
bacteremia ≥5 days.
As a composite comorbidity indicator, we calculated each
patient’s Elixhauser Comorbidity Index by screening for 31
comorbidity diagnoses among ICD-10 codes documented prior to
the index date23. To compare survival distributions for primary
endpoint of 1-year mortality (measured from date of hospital
admission to account for in-hospital deaths), we examined
univariate associations with potential demographic, infection type
and medical comorbidity confounders. Variables with p < 0.1 in
univariate analyses were integrated into a multivariate cox
proportional hazards model. “Drug abuse” was excluded from
Elixhauser Comorbidities as this risk factor was already captured
under ‘injection drug use origin’. Covariates were assessed using
backwards stepwise regression, for violation of the proportional
hazards assumption and assessed using log-negative-log survival
plots. Hazard ratios (HRs) and 95% conﬁdence intervals were
calculated. Descriptive statistics were calculated using SPSS v26
(Chicago, IL). Figures were created using GraphPad Prism 9 (San
Diego, CA).
Identiﬁcation, susceptibility testing and banking of S. aureus
isolates. S. aureus clinical isolates were cultured and analyzed in
the BJH clinical microbiology laboratory as part of the routine
medical care. All isolates recovered from BSI are routinely stored
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(IDU-BSI cases)

(non-IDU BSI controls)

154 patients with IDU-associated invasive
staphylococcal infections

92 patients with community cases of
invasive staphylococcal infection

55 index culture isolates
from prospectively
identified cases

99 index culture isolates
from retrospectively
identified cases

28 index culture isolates
from prospectively
identified cases

20 surveillance isolates
from subsequent infections
(same patient and same
MLST)

20 surveillance isolates
from subsequent
infections (same patient
and same MLST)

3 surveillance isolates from
subsequent infections
(same patient and same
MLST)

154 index culture isolates, 40 surveillance isolates from
physician identified cases of IDU-associated S. aureus infections
had whole genome sequences available for analysis

63 index culture isolates
from retrospectively
identified cases

1 surveillance isolates
from subsequent
infections (same patient
and same MLST)

91 index culture isolates, 4 surveillance isolates from invasive S.
aureus infections not associated with injection drug use, had
whole genome sequences available for analysis.

Fig. 1 Isolate Classiﬁcation. Flowchart and classiﬁcation of study patients based on injection drug use history, study period, and subsequent episode of
recurrent S. aureus infection. Abbreviations: BSI, bloodstream infection; IDU, injection drug use; IDU-BSI, injection drug use associated bloodstream
infection; MLST, multilocus sequence type.

by the BJH clinical laboratory at −80 °C in skim milk until
recovered for analysis. The identiﬁcation of banked isolates was
done using VITEK MS MALDI-TOF MS v2.3.3. Methicillin
resistance was determined using PBP2a testing (Alere), and, for
isolates from blood cultures, mecA detection using the Verigene
BC-GP assay (Luminex), in addition to cefoxitin disk diffusion.
Susceptibility testing for cefoxitin (FOX), clindamycin (CLI),
doxycycline (DOX), erythromycin (ERY), and trimethoprimsulfamethoxazole (SXT) was performed by the disk diffusion
method according to CLSI guidelines24. Isolates were classiﬁed as
“index” (the ﬁrst isolate obtained per patient) or “surveillance”
(isolates identiﬁed subsequent to index isolates). Isolates were
cross-referenced with medical records from the above case analysis and classiﬁed as IDU-BSI and non-IDU BSI cases, respectively (Fig. 1). IDU-BSI isolates were from IDU-BSI cases
identiﬁed above. Non-IDU BSI isolates were selected among cases
occurring during the study period in patients with no history of
drug use, and matched to IDU-BSI isolates according to isolation
date and patient residency (rural versus urban zip code). For
secondary analyses, non-IDU BSI isolates chosen for WGS were
subclassed into “CLABSI” (deﬁned as cases in which central line
venous access present at index date) or “cBSI” (deﬁned as BSI not
associated with IDU or central lines access).
Whole-genome sequencing (WGS) and genomic analysis. Illumina sequencing was performed on genomic DNA extracted
from a subset of clinical isolates (Fig. 1). Genome assembly and
analysis, including core genome alignment, multilocus sequence
typing (MLST), and identiﬁcation of antimicrobial resistance and
virulence factor genes, were performed based on well-established
processing pipelines25. Isolates were propagated on sheep’s blood
agar, and S. aureus isolate genomic DNA was extracted with the
Qiagen Bacteremia Kit (Qiagen, Germantown, MD, USA)
according to the manufacturer’s instructions. A total of 5 ng/uL of
DNA was used as input for Illumina sequencing libraries with the
Nextera kit (Illumina, San Diego, CA, USA). Pooled libraries were
sequenced on a NextSeq HighOutput platform (Illumina) to
obtain 2 × 150 bp reads. Following demultiplexing by barcode,

reads had adapters removed with Trimmomatic v0.3826. Reads
were then assembled into draft genomes using de-novo assembler
Unicycler v0.4.727. Scaffolds.fasta ﬁles were used for downstream
analysis. Assembly statistics was quantiﬁed using QUAST v4.528.
Whole-genome sequence read ﬁles are uploaded to NCBI under
BioProjects PRJNA694991 and PRJNA695316.
Species identity of each genome was conﬁrmed using the
ANIm method from pyANI v0.2.729. ANIm ≥96% compared to
the S. aureus reference genome (strain NCTC 8325,
GCF_000013425.1) was used as the species cutoff. In silico screen
for antibiotic resistance genes and multilocus sequence typing
(MLST) was performed with ResFinder v4.030 and MLSTcheck31, respectively. Prokka v1.13.732 was run on scaffold ﬁles
to identify open reading frames >500 bp in length. Scaffolds were
screened for the presence of genes of interest with BLAST using
the following parameters [−evalue 1e − 10 -perc_identity 90
-gapopen 5 -gapextend 5] and a cutoff of >90% amino acid
identity. Screened genes were selected a priori according to their
predicted role in disease, based on literature review33,34 and are
listed in Supplementary Data 1.
Phylogenetic and clonal analysis. For phylogenetic analysis, the
gff ﬁles produced by Prokka were used to construct a core genome alignment with Roary v3.1335. The alignment was used to
generate a maximum-likelihood tree with raxML v8.2.1136, and
visualized with iTOL37. For clonality analysis, Snp-sites v2.4.038
was used to remove indels and create multiFASTA alignment
containing the single nucleotide polymorphism (SNP) sites for
each core genome. Pairwise SNP counts between isolates were
calculated and plotted. SNP distances of isolates repeatedly
obtained from the same patient were used as reference, to
empirically determine SNP distance cutoffs indicating clonal
transmission. SNP distances between surveillance isolates
obtained from the same patient served as reference to empirically
determine a cutoff to deﬁne a clonal relationship between isolates
obtained from different individuals. Interactions that met the
cutoff were visualized using Cytoscape v4.039. Source data are
available in Supplementary Data 2.
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Fig. 2 Comparing the clinical traits and IDU-BSI and non-IDU BSI. a Number of unique patients with S. aureus IDU-BSI and non-IDU BSI (bars), and 90day rolling average proportion of total BSI cases that are IDU-associated (line) identiﬁed in BJH from 1/1/2016 to 12/31/2019. b Duration in days of S.
aureus bacteremia among adults stratiﬁed by IDU-BSI and non-IDU BSI. c Among BSI cases, AMA discharges and prolonged bacteremia (≥5 days) was
more common among IDU-BSI with lower rates of completion of standard of care intravenous (IV) antibiotics but did not translate into higher 1 year
mortality rates. d Kaplan–Meier survival curves comparing S. aureus IDU-BSI and non-IDU BSI with number at risk below the graph.

Statistics and reproducibility. Unless otherwise stated, comparisons of categorical data were performed by Fisher’s exact test,
while comparisons of continuous variable were tested using the
Mann-Whitney U test. All tests were two‐tailed, and statistical
signiﬁcance was deﬁned as p ≤ 0.05 or a 95% conﬁdence interval
(CI) excluding 1.00 for an odds ratio (OR). Statistical analyses
were performed on JMP Pro software (v15) or R software40.
Results
Clinical characteristics of IDU-BSI. We identiﬁed 173 and 1261
hospitalizations for S. aureus IDU-BSI and non-IDU cBSI,
respectively, from January 2016 through December 2019. The
proportion of cases associated with IDU increased from 9.1% in
2016 to 13.4% in 2019, with 12.1% of BSI cases being IDU-BSI
during the study period (Fig. 2a). However, IDU-BSI composed
25.7% of cases of prolonged bacteremia (i.e., culture-proven
bacteremia lasting ≥5 days), including 46.1% of cases with bacteremia lasting 9 days (Fig. 2b). Supplemental Table 1 summarizes patient characteristics by BSI type. IDU-BSI patients were
younger, and more likely to have infective endocarditis
(p < 0.001), while non-IDU BSI cases were more likely to have
CLABSI (p = 0.004). Though the rate of some comorbidities
differed between groups, there was no signiﬁcant difference in the
mean Elixhauser Comorbidities Index (p = 0.565, Supplementary
Table 1). Compared to non-IDU BSI cases, IDU-BSI cases were
more likely to experience prolonged bacteremia (p < 0.001) and to
leave the hospital against medical advice (AMA) (p < 0.001),
while being less likely to complete a full course of intravenous
antibiotic therapy (p < 0.001) (Fig. 2c). Despite this, IDU-BSI
cases exhibited decreased 30-day, 90-day and 1-year unadjusted
mortality compared to non-IDU BSI counterparts (p < 0.001 for
all comparisons) (Fig. 2c, d). 1-year mortality remained lower
among IDU-BSI patients after adjusting for sex, age, and presence
4

of clinically relevant Elixhauser Comorbidities (aHR 0.78; 95% CI
0.62–0.98, p 0.021, Supplementary Table 2).
Clinical characteristics of cases included in WGS cohort. We
obtained genome sequences from 289S. aureus isolates from
patients with S. aureus endovascular infections. These included
245 index and 44 surveillance isolates (Supplementary Table 1).
The demographic and clinical characteristics of patients with
cases associated with index IDU and non-IDU isolates chosen for
WGS (n = 154 and 91, respectively), are compared in Table 1.
Sequenced S. aureus IDU-BSI strains occurred among younger
patients who were more likely to experience homelessness
(p < 0.001), and to be co-infected with hepatitis B (HBV)
(p = 0.017), hepatitis C (HCV) (p < 0.001), or HIV (p = 0.002).
IDU-BSI cases were more likely to be associated with infective
endocarditis (p < 0.001), and less likely to be associated with the
presence of a central line at diagnosis or to present without
metastatic sites of infection (“isolated bacteremia”) (p < 0.001).
There was no signiﬁcant difference in the occurrence of osteomyelitis, necrotizing fasciitis, or septic arthritis. The investigated
characteristics of IDU-BSI and non-IDU BSI cases included in
WGS analysis, were comparable to those of corresponding subgroups in the total BJH BSI cohort (Supplementary Table 1).
Phylogenetic analysis of BSI isolates. BSI isolate genomes
represented 26 different multilocus sequence types (ST), which
included 10 ST groups (i.e., groups of single-locus or double-locus
MLST variants sharing a common ancestor) containing at least
ﬁve index isolates (Fig. 3 and Supplementary Table 3). The distribution of these ST groups between IDU-BSI and non-IDU BSI
index isolates was not signiﬁcantly different (p = 0.081, by Fisher
exact test). The MRSA-associated ST groups ST8/1181/1750 and
ST5/840, composed 67.1% and 25.2% of index isolates,
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Table 1 Demographics of index isolates included for wholegenome sequencing.
Non-IDU
patients,
N = 91
Demographics
Age (mean, SD)
58 ± 14
Female
34 (37.4%)
Homeless
0 (0.0%)
Discharged AMA
0 (0.0%)
Substance use patterns
Opioid use (fentanyl or
0 (0.0%)
heroin)
Methamphetamine use
0 (0.0%)
Comorbidities
Hepatitis B virus infection
0 (0.0%)
Hepatitis C virus infection
1 (1.1%)
HIV Infection
0 (0.0 %)
Elixhauser comorbidities
9.0 (3.4)
(mean, SD)
Clinical syndromes caused by Isolate
Infective endocarditis
21 (23.0%)
Osteomyelitis
17 (18.6%)
Septic arthritis
10 (10.9%)
Necrotizing skin and soft
6 (6.6%)
tissue infection
Isolated bacteremia
46 (50.5%)
S. aureus infection characteristics
1 ± 0.2
Hospital Day of S. aureus
Isolation for WGS (mean
day, SE)
Duration of bacteremia (mean 3 ± 0.3
days, SE)
Central line associated
38 (41.8%)
bacteremia
Outcomes
1 year Mortality
27 (29.7%)

PWID,
N = 154

P

38 ± 10
77 (50%)
12 (7.8%)
43 (27.9%)

<0.001
0.045
<0.001
<0.001

142 (92.2%)

<0.001

48 (31.1%)

<0.001

6 (3.9%)
95 (61.7%)
10 (6.5%)
8.6 (3.9)

0.017
<0.001
0.002
0.484

99 (64.3%)
33 (21.4%)
27 (17.5%)
22 (14.2%)

<0.001
0.576
0.149
0.054

15 (9.7%)

<0.001

1 ± 0.3

0.641

4 ± 0.3

0.122

1 (0.6%)

22 (14.3%)

ARTICLE

The median time between index dates of cases within a cluster
was 28 days (mean 95 days, range 1–355 days), compared to a
median of 293 days (mean 393, range 1–1394 days) between cases
in differing clusters (p = <0.0001). Fourteen of the 20 clusters
(70%) demonstrated HCV seroconcordance between ≥2 individuals (Fig. 4b). Lastly, compared to cohort individuals not
assigned to transmission clusters, patients in clusters were more
likely to be under the age of 50 (p < 0.001), to experience
prolonged bacteremia (p < 0.001), to be co-infected with HIV or
HCV (p < 0.001), and to use injection opioids (p < 0.001) (Fig. 4d).
Together these data describe multiple geographically and
temporally localized S. aureus transmission networks, which
share objective epidemiologic and biologic markers of needle
sharing (i.e., report of IDU, HIV/HCV serology), exclusively
among PWID.
Secondary analysis reveals nonequivalent distribution of ST
groups between cBSI and IDU-BSI isolates. As stated above,
primary analysis revealed no difference in the distribution of ST
groups between IDU-BSI to non-IDU BSI isolates. However, we
noted a high incidence of CLABSI cases among the non-IDU
cases in some lineages, such as ST398/4163 (Fig. 3). When nonIDU BSI isolates were sub-grouped into CLABSI and cBSI
(n = 36 and n = 53, respectively), ST group distribution differed
between cBSI and IDU-BSI cases (Supplementary Table 3,
p = 0.035, Fisher exact test). When comparing observed to
expected occurrence, underrepresented ST groups (i.e., ST groups
observed at <75% of expected occurrence within a BSI subtype)
were ST188, ST398/4163, ST45/256/536, ST97, and ST15/582 for
cBSI, and ST30/39 and ST72 for IDU-BSI (Fig. 5a, b). These
ﬁndings were consistent with differential selection of staphylococcal lineages according to BSI type.

<0.001

0.082

AMA against medical advice, HIV human immunodeﬁciency virus, IDU injection drug use, PWID
person who injects drugs, SD standard deviation, SE standard error, WGS whole-genome
sequencing.

respectively. The most common non-MRSA ST groups, ST398/
4163 and ST15/582, composed 14.0% and 10.5% of index isolates,
respectively.
Identiﬁcation and characterization of staphylococcal IDU-BSI
transmission clusters. We next determined the clonality of BSI
isolates according to pairwise SNP distance. To standardize
clonality analysis across our phylogenetically diverse cohort, we
analyzed the 1782 genes shared by all genomes in our cohort (i.e.,
the ‘core genome’). By compiling the pairwise core genome SNP
distances between index isolates and between surveillance isolates
obtained from single individuals, we determined that isolates
likely resulted from clonal transmission if their core genomes
differed by <15 SNPs (Fig. 4a). Using this conservative cutoff, we
identiﬁed 20 transmission clusters containing 46 index isolates,
with all but one isolate being from IDU-BSI cases (Fig. 4b). These
represented 29.2% (45/154) of all IDU-BSI isolates, but 78.6%
(11/14) and 100% (3/3) of ST398/4163 and ST672 IDU-BSI isolates, respectively.
We subsequently investigated demographic and clinical
features that could support an epidemiological link between
cases within transmission clusters. Though patients in the entire
cohort resided in 117 zip codes throughout Missouri and Illinois,
41/46 patients in transmission clusters shared or lived adjacent to
the zip codes of other individuals within their cluster (Fig. 4c).

ST groups lacking multiple canonical virulence factors are
underrepresented among cBSI isolates. Since genomic repertoire inﬂuences the differential ability of microbes to cause different disease forms, we evaluated for the presence of genomic
antibiotic resistance and canonical staphylococcal virulence
determinants in our cohort (Supplementary Data 3). As expected,
gene distribution was principally according to ST group lineage,
and the presence of resistance determinants correlated with lab
susceptibility testing (Fig. 3 and Fig. 5c, d). The distribution of
MRSA isolates did not differ between cBSI (20/53), CLABSI (8/
36) and IDU-BSI isolates (64/154) (p = 0.094, Fisher exact test).
Regarding the a priori selected list of ﬁtness and virulence
determinants (Supplementary Material 1), 100% of genomes
contained the genes involved in iron acquisition and desiccation
tolerance, and many genes involved in toxin production, immune
evasion, and adhesion/bioﬁlm formation were present in greater
than 95% of isolates (Supplementary Table 1). For genes that
occurred in less than 95% of total isolates, sequence types that
were underrepresented in cBSI (Fig. 5c) lacked genes in all other
sequences types (Fig. 5d, e), such as the staphylokinase and
hyaloronidase genes sak and hysA, respectively. ST398/4163 isolates demonstrated the greatest paucity of canonical virulence
factors (Fig. 5c).
Discussion
To our knowledge, this is the ﬁrst molecular epidemiological
analysis comparing S. aureus isolates acquired from IDUassociated bloodstream infections (IDU-BSI) and conventional
BSI (cBSI). Our case-control approach allowed us to identify
characteristic features of IDU-BSI that are critical to consider in
developing future investigations and interventions for this
emerging disease.
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Firstly, WGS revealed that person-to-person transmission of
multiple MRSA and methicillin susceptible S. aureus (MSSA)
lineages are fueling the epidemic of invasive infections among
PWID in Missouri and Southern Illinois. The transmission of S.
aureus within IDU networks had been previously proposed, but
evidence was limited to studies with low-resolution molecular
methods or small cohort sizes10–13. More recently, Packer et al.14
employed WGS to investigate MRSA colonization and disease
isolates in PWID in Bristol, United Kingdom. They identiﬁed a
single ST5 lineage predominated in their cohort, but their study
was not designed to establish whether this phenomenon was
exclusive to PWID, to identify transmission events, or to investigate dynamics of other lineages. By applying strict, empiricallyderived clonality criteria comparable to those employed by other
groups41, we found strong evidence of clonal expansion of
pathogenic S. aureus IDU-BSI isolates, and that
epidemiologically-linked BSI transmission clusters almost exclusively occurred among PWID. In multiple clusters, ≥3 IDU-BSI
6

isolates shared a common ancestor, reﬂecting that staphylococcal
IDU-BSI cases can result from community outbreaks, similar to
HCV and HIV outbreaks linked to needle sharing practices
among PWID42. Though we detected clonal expansion only
among IDU-BSI cases, the relative underrepresentation (and,
thus, reduced relative sequencing depth) of non-IDU BSI isolates
in our genomic analysis could have decreased the likelihood of
discovering clusters among non-IDU BSI cases, as well. However,
the substantial difference in the proportion of matched IDU BSI
and non-IDU BSI isolates belonging to transmission clusters (i.e.,
29.2% [45/154] versus 1.1% [1/91]) ﬁrmly supports that clonal
expansion is characteristic of the IDU-BSI epidemic.
Remarkably, some lineages (e.g., ST398/4163, ST672) were
strongly associated with these IDU-BSI transmission clusters,
suggesting that their pathogenicity depends heavily on IDUassociated risk factors. Many staphylococcal lineages underrepresented among cBSI cases lacked various canonical virulence
factors associated with staphylococcal pathogenesis, suggesting a
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selective pressure favoring “well-equipped” lineages during conventional pathogenesis. Others have observed similar enrichment
of virulence factors in invasive versus colonizing S. aureus isolates, with implicated virulence factors having a cumulative effect
on invasiveness43. Conversely, direct inoculation of bacteria into
the bloodstream and bypass of early stages of cBSI (e.g., abscess
formation, mucosal invasion, early immune evasion, etc.), permits
disease by “less virulent” lineages. The comparable-to-lower
mortality of invasive Staphylococcal disease among PWID relative to disease in non-PWID popualtions19,44, despite the former’s association with prolonged bacteremia and often
suboptimal antibiotic therapy45,46, may largely be due to the fact
that the former occurs in a younger patient population. However,
it is conceivable that the portion of IDU-BSI associated with
lineages with reduced superantigen production or toxin secretion
(both implicated in S. aureus sepsis) may also contribute to
tempering IDU-associated infection severity. These implications,
however, should not detract from the morbidity of IDU-BSI with
“less virulent” lineages, as they were repeatedly implicated in BSI
complications, including endocarditis, osteomyelitis, and septic
arthritis in our cohort. Additional observational surveys of larger
cohorts and preclinical research examining lineage-dependent
pathogenesis, are required to conﬁrm the impact of “less virulent”
lineages in S. aureus invasive disease.
A notable example of a “less virulent” lineage underrepresented
among cBSI cases was the clonal complex 398 (CC398), which
includes ST398 and ST4163 (Supplementary Table 3). CC398
isolates in our cohort characteristically demonstrated macrolide
resistance putatively mediated by ermT (Fig. 2), but they all
lacked superantigens and many other canonical virulence factors.
CC398 was ﬁrst identiﬁed as a PVL-negative MRSA lineage in
livestock in Europe, but was subsequently detected among MSSA
colonizing diverse settings including community households and
inmates in a jail holding tank47–49. Rarely implicated in human
disease, CC398 was identiﬁed in only one of 81 MSSA soft tissue
infections in a prior study in our area50. By contrast, CC398 was
the most abundant exclusively MSSA lineage in our BSI cohort.
CC398 was strongly associated with IDU transmission clusters,
suggesting the lineage depends on intravenous inoculation in
order to cause BSI. Indeed, though several non-IDU BSI cases
were linked to CC398 in our cohort, they were almost exclusively
CLABSI cases, where nosocomial bloodstream inoculation likely
occurred. This demonstrates how preclinical models of IDU-BSI
must account for the broader array of “less virulent” lineages that
may be historically underrepresented among cBSI cases.
The dynamics mediating the high degree of relatedness among
S. aureus IDU-BSI isolates may serve as a target for curbing the
IDU-BSI epidemic and merits close examination. One explanation is that the intimate interactions characteristic to some PWID
populations, such as congregation in non-traditional housing,
sharing of drug use paraphernalia and transactional sexual
exchanges, which may predispose to clonal expansion through
sequential asymptomatic carriage within a PWID network. This,
in turn, increases the likelihood that two individuals in a network
develop IDU-BSI due to related S. aureus strains. However, this
model presumes periods of genomic pool expansion during
asymptomatic carriage punctuated by pool bottlenecking during
colonization of new hosts and subsequent introduction into the
bloodstream. It is unclear whether these population shifts would
result in BSI cases with isolates displaying the high degree of
genomic relatedness as what we observed between isolates subsequently obtained from a single BSI case and isolates within a
single IDU-BSI transmission cluster (i.e., <15 core genome SNPs).
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Fig. 5 Differential distribution of phylogenetic subgroups and canonical virulence factor genes among different BSI types. a Unrooted version of the
maximum-likelihood phylogenetic tree shown in Fig. 1, with each MRSA or MSSA isolate represented by a ﬁlled or empty circle, respectively. Pie charts
represent the portion of each ST subgroup that was obtained for cBSI (solid), CLABSI (stippled) or IDU-BSI (white) cases. Only subgroups with ≥5 isolates
are represented in pie charts. All other isolates (n = 19) were grouped as “Other”. b Fold differences of the observed versus expected incidence of each ST
subgroup among cBSI (black bars), CLABSI (gray bars) and IDU-BSI (white bars) isolates in our cohort. No ST188 strains were identiﬁed among cBSI
isolates. In panels a and b, (*) and (#) denote ST groups whose incidence was <75% of expected among cBSI and IDU-BSI isolates, respectively. c–e
Representation of the genome content of ST subgroups underrepresented in cBSI (panel c), subgroups underrepresented in IDU-BSI (panel d) and all other
subgroups (panel e). Each column represents a genome. First row denotes ST subgroup, with the genomes grouped as “Other” are lacking labels. Second
row denotes MRSA (ﬁlled) or MSSA (empty) isolates. Subsequent rows show the presence (ﬁlled square) of canonical virulence factor genes, which are
subclassiﬁed according to their roles in either immune evasion (blue), toxin production (red), or bioﬁlm formation (green). Source data for this ﬁgure is
derived from analysis of genome sequences uploaded at NCBI under BioProjects PRJNA694991 and PRJNA695316 and is available in tabular form in
Supplementary Data 3.

An alternative explanation is subsequent infections resulting from
sharing of drug preparation or delivery equipment colonized with S.
aureus. Indeed, Kasper et al. previously found that 14% of cookers/
ﬁlters used for injection of controlled-release opioids in a community were contaminated with S. aureus which could have been
injected intravenously during routine substance use9. In either scenario, socioeconomic status factors such as homelessness and the
low accessibility of needle exchange services in Missouri (which is a
needle non-exchange state) may have contributed to the relatively
high prevalence of transmitted isolates in the current study.
A third explanation for the clonal nature of IDU-BSI isolates
would be bloodborne transmission. We conﬁrmed IDU-BSI was
associated with prolonged durations of bacteremia and frequent
AMA discharges. So, although S. aureus invasive infections are
8

generally considered to have acute and fulminant presentations,
these infections conceivably take a more chronic course in a)
individuals receiving intermittent, abbreviated antimicrobial
therapy resulting in a “lower-grade” bacteremia or b) BSI patients
with incompletely treated, secondary infections (e.g., endocarditis,
osteomyelitis, occult abscesses, etc.) that can serve as chronic
sources for recurrent bacteremia. Indeed, our cohort included an
individual who had clonal S. aureus isolates obtained from blood
specimens over a seven month period, without intervening
negative blood cultures. Furthermore, seven transmission clusters
contained IDU-BSI patients from whom clonal S. aureus isolates
were obtained from at least two separate hospitalizations. Thus,
IDU-BSI patients who defer medical attention could plausibly
serve as reservoirs for bloodborne transmission through sharing
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of needles or drug preparation equipment. This provocative
scenario requires further investigation, as it would shift priority
towards clearance of bacteremia as a means to curb IDU-BSI
propagation and inform the approach for assessing risk factors
for S. aureus BSI in this population.
Our investigation was limited to a single region where needle
exchanges are prohibited, thus, limiting the generalizability of our
ﬁndings. However, this represents a unique opportunity to examine
the indirect impact of social IDU mitigation strategies practiced in
other states on the BSI epidemic. Because the validity of contact
tracing is complicated by recall limitations and socioeconomic
instability often experienced by PWID, we were unable to validate
our genomically-derived transmission clusters with retrospective
contact tracing. However, our conservative SNP threshold for case
clustering was deliberately chosen to minimize false-positive effects.
Since our WGS cohort did not include isolates from nonendovascular host sites, we could not investigate whether asymptomatic colonization is a prerequisite for BSI among PWID. Further,
the impact of different inpatient interventions such as ICU admission or cardiac surgery which could affect mortality differences
between PWID and non-PWID groups was not assessed in this
study. Lastly, our follow-up was limited to data present in the
electronic medical record and out of hospital deaths which could
contribute to mortality differences would not be captured in this
study. Despite these limitations, the comparative design of our study
combined with robust clinical and genomic data provides valuable
insight into the epidemiological and pathophysiological impact of
the propagation of multiple S. aureus lineages among PWID.
Conclusion
We identiﬁed clonal expansion of multiple S. aureus lineages
among IDU-BSI isolates, but not non-IDU BSI isolates, in a
community with limited access to needle exchange facilities. In
the setting of expanding numbers of staphylococcal IDU-BSI
cases consideration should be given to treating IDU-associated
invasive staphylococcal infections as a communicable disease.
Reporting summary. Further information on research design is
available in the Nature Research Reporting Summary linked to
this article.
Data availability
The data that support the ﬁndings of this study are available within the paper and its
supplementary information ﬁles. The source data underlying Figs. 3, 4 & 5 are derived
from whole-genome sequencing of the strains in this project. Whole-genome sequence
read ﬁles are uploaded to NCBI under BioProjects PRJNA694991 and PRJNA695316.
Source metadata for Fig. 3 & 5 can be accessed as Supplementary Data 2. Source Data for
Fig. 4a can be accessed as Supplementary Data 3. The remaining source data on
individual patient outcomes and locations used in Figs. 2 and 4b–e cannot be provided
because it contains elements of protected health information and the ethical approval
does not cover placing individual patient level data into publicly open repositories.
Relevant portions of those data can be accessed from the authors upon relevant ethical
approval by contacting the corresponding author on reasonable request.
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